Erectile Dysfunction

Of course, all of this could be waived in a private consultation if the male patient is not, um, intending to have sex with a woman.

So your typical middle-aged GOP married guy can either jump through all the hoops or um, tell the pharmacist he's not going to have sex with a woman, and we'll just leave it at that.

# Posted by stilwell : 6:48 AM | << Home Syndication Join NPI We're looking for progressive activists who want to make a difference and share their ideas with the world.

NPI Home Infocenter Official Blog Feed (Atom) Official Blog Feed (RSS) NPI Multimedia Feed (RSS) Permanent Defense (RSS) Receive Email Digest when the Official Blog is updated: Previous Posts Vote for Darcy FBI raids GOP congressman's home Blitzer: The Swedish media is obsessed with VT kil...

The lighter side - The Postman Dodge Government promoted and enforced pregnancy U.S.

House passes Willd Sky bill Blogworthy, April 16th, 2007 (including reaction t...

AP moves hatchet piece against Edwards Guns versus Sudafed Drinking Liberally reaches 200 chapters Archives Select ...

About Cetrorelix Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach.

This peptide-based active substance was developed by the Company in cooperation with Nobel Prize winner Professor Andrew Schally of the U.S.

Veterans Administration in Miami.

Cetrorelix is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovulation stimulation/assisted reproductive technologies) in Europe, the USA and Japan.

It was launched on the market through Merck Serono in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

In addition to the Phase 3 program in BPH, cetrorelix is also in a Phase 2 program in this same indication in Japan, sponsored by the Company's partner, Shionogi as well as in a clinical program for endometriosis sponsored by Solvay.

About AEterna Zentaris Inc.

AEterna Zentaris Inc.

is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization.

News releases and additional information are available at http://www.aeternazentaris.com/.

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe ...